ENTERA BIO LTD ENTX
SHS · Common Stock · CUSIP M40527109
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 46.6m as of 2026-03-23, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $1.10.
Trends to Q1 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 10 |
| Q4 2022 | 13 |
| Q1 2023 | 10 |
| Q2 2023 | 13 |
| Q3 2023 | 13 |
| Q4 2023 | 11 |
| Q1 2024 | 16 |
| Q2 2024 | 16 |
| Q3 2024 | 18 |
| Q4 2024 | 15 |
| Q1 2025 | 19 |
| Q2 2025 | 20 |
| Q3 2025 | 22 |
| Q4 2025 | 22 |
| Q1 2026 | 26 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q2 2024 | 7 | 8 |
| Q3 2024 | 6 | 4 |
| Q4 2024 | 7 | 7 |
| Q1 2025 | 8 | 3 |
| Q2 2025 | 9 | 6 |
| Q3 2025 | 9 | 8 |
| Q4 2025 | 9 | 8 |
| Q1 2026 | 13 | 11 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q2 2025 | $950 | $0 | 0.00 |
| Q3 2025 | $40.9k | $0 | 0.00 |
| Q4 2025 | $14.7k | $0 | 0.00 |
| Q1 2026 | $0 | $0 | — |
Biggest buyers
| RENAISSANCE TECHNOLOGIES LLC | Added | +365.4k |
| CITADEL ADVISORS LLC | Added | +205.3k |
| XTX Topco Ltd | New | +131.6k |
| Seven Fleet Capital Management LP | Added | +70.2k |
| DIADEMA PARTNERS LP | New | +23.3k |
| HRT FINANCIAL LP | New | +15.5k |
| Parkman Healthcare Partners LLC | Added | +13.6k |
| JPMORGAN CHASE & CO | New | +7.2k |
| Persistent Asset Partners Ltd | New | +5.9k |
| UBS Group AG | Added | +3.2k |
Biggest sellers
| Point72 Asset Management, L.P. | Reduced | -1.2m |
| Schonfeld Strategic Advisors LLC | Reduced | -541.4k |
| MARSHALL WACE, LLP | Reduced | -431.6k |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Sold out | -64.9k |
| JANE STREET GROUP, LLC | Reduced | -41.1k |
| SUPERSTRING CAPITAL MANAGEMENT LP | Sold out | -17.1k |
| GOLDMAN SACHS GROUP INC | Sold out | -12.3k |
| GSA CAPITAL PARTNERS LLP | Sold out | -11.9k |
| HighTower Advisors, LLC | Reduced | -6.3k |
| BANK OF AMERICA CORP /DE/ | Reduced | -3.0k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
BIOTECHNOLOGY VALUE FUND L P
13D · may seek influence
new · filed 2026-08-04
Stated purposeThe Reporting Persons purchased the securities reported owned herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. April Securities Purchase Agreement and Registration Rights Agreement On April 1, 2026, … Full filing |
10.0% |
| OPKO HEALTH, INC. 13G · passive investor new · filed 2025-04-02 | 8.1% |
| TCG Crossover GP III, LLC 13G · passive investor new · filed 2026-08-04 | 7.1% |
| Vivo Opportunity Fund Holdings, L.P. 13G · passive investor new · filed 2026-08-04 | 6.9% |
Fell to 5% or below in the last year: Longitude Capital Partners V, LLC (4.6%, 2026-08-04), Seven Fleet Capital Management LP (4.1%, 2026-08-04), Point72 Asset Management, L.P. (2.6%, 2025-11-14)
Insider purchases and sales in Q1 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q2 2024 | 0 | — | 0 | — | — |
| Q3 2024 | 0 | — | 0 | — | — |
| Q4 2024 | 0 | — | 0 | — | — |
| Q1 2025 | 0 | — | 0 | — | — |
| Q2 2025 | 0 | — | 0 | — | — |
| Q3 2025 | 0 | — | 0 | — | — |
| Q4 2025 | 1 | $19.9k | 0 | — | — |
| Q1 2026 | 4 | $121.0k | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2026-03-09 | Germano Geno J Director | Bought | $26.0k20.0k shares |
| 2026-03-05 | Ellis Sean Director | Bought | $12.3k10.0k shares |
| 2026-02-12 | Rubin Steven D Director | Bought | $7.5k5.0k shares |
| 2026-02-10 | Germano Geno J Director | Bought | $29.8k20.0k shares |
| 2026-02-10 | Taitel Haya Director | Bought | $11.1k7.5k shares |
| 2026-02-09 | Ellis Sean Director | Bought | $22.3k18.0k shares |
| 2026-02-09 | Rubin Steven D Director | Bought | $12.0k10.0k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q1 2026
| Manager | Shares | Change |
|---|---|---|
| Knoll Capital Management, LLC 3.43% of their portfolio | 5.9m $6.5m | Unchanged |
| RENAISSANCE TECHNOLOGIES LLC 0.00% of their portfolio | 473.4k $525.5k | Added +365.4k |
| Parkman Healthcare Partners LLC 0.03% of their portfolio | 288.7k $320.4k | Added +13.6k |
| CITADEL ADVISORS LLC 0.00% of their portfolio | 245.6k $272.6k | Added +205.3k |
| Seven Fleet Capital Management LP 0.07% of their portfolio | 205.5k $228.2k | Added +70.2k |
| MARSHALL WACE, LLP 0.00% of their portfolio | 195.8k $217.3k | Reduced -431.6k |
| NORTHERN TRUST CORP 0.00% of their portfolio | 146.9k $163.0k | Reduced -1.8k |
| XTX Topco Ltd 0.00% of their portfolio | 131.6k $146.1k | New |
| Schonfeld Strategic Advisors LLC 0.00% of their portfolio | 55.2k $61.3k | Reduced -541.4k |
| SIGNATURE ESTATE & INVESTMENT ADVISORS LLC 0.00% of their portfolio | 47.3k $52.5k | Unchanged |
| HighTower Advisors, LLC 0.00% of their portfolio | 36.8k $40.9k | Reduced -6.3k |
| JANE STREET GROUP, LLC 0.00% of their portfolio | 32.9k $36.5k | Reduced -41.1k |
| DIADEMA PARTNERS LP 0.01% of their portfolio | 23.3k $25.8k | New |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 21.1k $23.5k | Unchanged |
| Gem Investment Advisors, LLC 0.02% of their portfolio | 19.1k $21.2k | Unchanged |
| HRT FINANCIAL LP 0.00% of their portfolio | 15.5k $17.0k | New |
| Point72 Asset Management, L.P. 0.00% of their portfolio | 12.4k $13.7k | Reduced -1.2m |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 12.0k $13.3k | Reduced -3.0k |
| PNC Financial Services Group, Inc. 0.00% of their portfolio | 10.0k $11.1k | Unchanged |
| JPMORGAN CHASE & CO 0.00% of their portfolio | 7.2k $7.2k | New |
| Persistent Asset Partners Ltd 0.00% of their portfolio | 5.9k $6.5k | New |
| UBS Group AG 0.00% of their portfolio | 3.2k $3.6k | Added +3.2k |
| MORGAN STANLEY 0.00% of their portfolio | 400 $444 | New |
| GROUP ONE TRADING LLC 0.00% of their portfolio | 51 $57 | Unchanged |
| Caitong International Asset Management Co., Ltd 0.00% of their portfolio | 20 $22 | New |
| SBI Securities Co., Ltd. 0.00% of their portfolio | 2 $2 | New |